Deltex Medical Group plc is in the April edition of the British Journal of Anaesthesia

Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), announced today that it intends to release its results for the year ended 31 December 2017 on 9 May 2018.

Further to the announcement of the online publication of the results of the FEDORA trial on 1 March 2018, the Company notes that the study was included in the April print edition of the British Journal of Anaesthesia.

A recorded lecture on the FEDORA trial by Professor Monty Mythen is available at no charge at https://www.topmedtalk.com/journal-club-the-fedora-trial/

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Deltex Medical Group Plc

    More articles like this

    Deltex Medical Group Plc

    Deltex Medical Group plc in a strong financial position

    Nigel Keen, Chairman of Deltex Medical, commented: “The successful £2,050,000 fund raising in February 2018 has put the Group in a stronger financial position – allowing us to improve our business structure. “We made a number of changes

    Deltex Medical Group Plc

    INTERVIEW: Deltex Medical Group New CEO Andy Mears

    Deltex Medical Group Plc (LON:DEMG) New CEO Andy Mears talks to DirectorsTalk about his new position. Andy talks about his background, how he thinks Deltex is positioned, his plans for the next 12 months and the challenges and

    Deltex Medical Group Plc

    Deltex Medical Group plc New Chief Executive

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, announced today that Ewan Phillips has resigned as Chief Executive and as a Director of the Company with immediate effect. Mr. Phillips recently approached Deltex’s Chairman indicating